March 27, 2023 — Allergy Therapeutics (AIM: AGY), the fully integrated commercial biotechnology company specialising in allergy vaccines, today announces that the first application of VLP Peanut in peanut-allergic patients has commenced with the Group’s innovative, short-course peanut allergy vaccine candidate in the Phase I PROTECT trial. The first-in-human study is evaluating the safety and tolerability of VLP Peanut in healthy and peanut-allergic adult subjects and exploring preliminary proof of efficacy.
Allergy Therapeutics’ wholly-owned, subcutaneous, recombinant vaccine candidate incorporates novel virus-like particle (VLP) technology, which enhances the body’s immune response by making the peanut allergen resemble an inactive virus.
About Allergy Therapeutics
Allergy Therapeutics is an international commercial biotechnology company, headquartered in the UK, focussed on the treatment and diagnosis of allergic disorders, including aluminium-free immunotherapy vaccines that have the potential to cure disease. The Group sells proprietary and third-party products from its subsidiaries in nine major European countries and via distribution agreements in an additional ten countries. Its broad pipeline of products in clinical development includes vaccines for grass, tree, house dust mite and peanut. For more information, please see www.allergytherapeutics.com.